Organisation paid for research Program year 2025 Source: CMS Open Payments

Pioneer Clinical Studies

Neither a doctor nor a teaching hospital

Research payments

$2,532,796

122 payments

Through program year 2025, Pioneer Clinical Studies is reported as receiving $2,532,796 in research payments, across 122 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$1,595,115	68
2024	Research	$852,624	36
2023	Research	$65,564	15
2022	Research	$19,494	3

Breakdown

Who paid Research payments · program years 2022–2025

Moderna TX, Inc. $2,282,311 78 payments
Genentech, Inc. $126,218 21 payments
GlaxoSmithKline, LLC. $76,376 19 payments
Novartis Pharmaceuticals Corporation $27,325 1 payment
Eli Lilly and Company $19,066 2 payments
Ge Healthcare $1,500 1 payment

Studies the money was for Research payments · program years 2022–2025

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $1,545,093 60 payments
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $737,218 18 payments
Phase Iia $107,107 15 payments
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $76,376 19 payments
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) $27,325 1 payment
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough $19,111 6 payments
Taltz Psa Observational Study $9,713 1 payment
Taltz Psa Observational Study $9,353 1 payment
Flurpiridaz Comparison Study $1,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.